Clinical Trial Update: An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Open-label, multicenter Phase 1/2 trial evaluating PARP inhibitor E7449 as a single agent and in combination regimens for advanced solid tumors, including ovari…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Malignancy Low-grade
• Malignant Solid Tumor
• Melanoma
• Ovarian Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• E7449 (E7449)
• PACLITAXEL (PACLITAXEL)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Eisai Limited | Conditions: Malignant Solid Tumour, Ovarian Cancer | Phase 1, Phase 2 | Status: COMPLETED